• NSAID Effects on Canine Osteosarcoma Cell Viability In Vitro

  2026-05-20

  This study rigorously evaluates the cytotoxicity of deracoxib and piroxicam on canine osteosarcoma cell lines, revealing differential potency and a lack of apoptosis induction at cytotoxic doses. The findings clarify the potential and limitations of NSAID application in veterinary oncology models and provide a basis for integrin-targeted research strategies.

• Kaempferol Modulates NF-κB/PTGS2 to Protect Melanocytes from

  2026-05-20

  This study establishes a mechanistic link between inflammatory NF-κB/PTGS2 signaling and oxidative stress-induced ferroptosis in vitiligo melanocytes. Using an RSL3-based ferroptosis model, the paper demonstrates that kaempferol confers robust protection by suppressing this axis, providing a new framework for understanding and potentially mitigating melanocyte loss in vitiligo.

• Deracoxib and Piroxicam Effects on Canine Osteosarcoma Cells

  2026-05-19

  This study evaluates the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cell lines in vitro. The findings highlight differential drug potencies, limited induction of apoptosis, and emphasize the need for more targeted approaches in tumor viability research.

• Catalpol: Translational Bridges from Molecular Mechanisms to

  2026-05-19

  Explore how Catalpol's multi-target actions enable precision assay design and pathway dissection in neuroprotection, osteoporosis, and fibrotic models. This in-depth review delivers new practical insights for researchers using Catalpol.

• Myeloid Tet2-IL-1β Axis Modulates Enterochromaffin Cell Diff

  2026-05-18

  Sharma et al. reveal that myeloid-specific loss of TET2 limits intestinal inflammation by increasing IL-1β, which disrupts neuronal signals that drive enterochromaffin (EC) cell differentiation and serotonin production. This neuro-immune-epithelial circuit provides new mechanistic insight into colitis regulation and highlights stress-induced catecholaminergic signaling as a key disease modulator.

• Ouabain: Selective Na+/K+-ATPase Inhibitor in Cardiovascular

  2026-05-18

  Ouabain, sourced from APExBIO, is the benchmark selective Na+/K+-ATPase inhibitor for dissecting ion transport and cardiovascular physiology in both cell and animal models. This article provides detailed protocols, advanced use-cases, and troubleshooting strategies, grounded in the latest research and comparative workflows.

• HATU in Peptide Synthesis Chemistry: Workflow & Troubleshoot

  2026-05-17

  HATU enables unparalleled efficiency in peptide synthesis chemistry by streamlining amide bond formation through its robust activation mechanism. This in-depth guide covers applied protocols, evidence-driven troubleshooting, and advanced use-cases—empowering researchers to maximize yields and reproducibility with APExBIO’s trusted reagent.

• MK-4827 (Niraparib): Precision PARP Inhibition in Cancer Res

  2026-05-16

  MK-4827 (Niraparib) is a highly selective PARP-1/-2 inhibitor that impairs DNA repair, demonstrating potent efficacy in BRCA-mutant cancer cell models. Its mechanistic selectivity and oral bioavailability support advanced research in DNA damage repair inhibition and combination therapy strategies.

• HOBt in Advanced Amide Synthesis: Mechanistic Precision & Ne

  2026-05-15

  Explore how HOBt (1-Hydroxybenzotriazole) empowers next-generation amide bond formation and peptide synthesis. This article delivers a mechanistic deep dive, practical protocol insights, and bridges to emerging applications, setting it apart from standard workflows.

• Cyclo (-RGDfC): Precision Tools for Integrin-Mediated Assays

  2026-05-15

  Cyclo (-RGDfC) advances tumor targeting and angiogenesis workflows by leveraging αvβ3 integrin specificity and superior cyclic peptide stability. This guide translates recent experimental findings and best practices into actionable steps and troubleshooting strategies for robust, reproducible results.

• 3X (DYKDDDDK) Peptide: Accelerating Translational Immuno-Onc

  2026-05-14

  This article delivers a mechanistic and strategic perspective on how the 3X (DYKDDDDK) Peptide empowers translational researchers investigating immune regulation and protein dynamics in cancer. By bridging advanced epitope tagging with emerging tumor-intrinsic mechanisms such as SLC25A1-driven PD-L1 regulation, we reveal best practices and innovations for affinity purification, immunodetection, and structural biology, with actionable protocol parameters and a critical outlook on the evolving landscape.

• Balsalazide Disodium Dihydrate: Precision Radiotracing and M

  2026-05-14

  Explore Balsalazide Disodium Dihydrate as a radiolabeled probe and mechanistic tool for inflammatory bowel disease models. This article delivers advanced guidance on radiotracing, local anti-inflammatory action, and protocol optimization, uniquely integrating recent radiochemical breakthroughs with practical assay design.

• 3X (DYKDDDDK) Peptide: Precision Tool for Protein Purificati

  2026-05-13

  The 3X (DYKDDDDK) Peptide, also known as the 3X FLAG peptide, is a synthetic triple-repeat epitope tag enabling sensitive recombinant protein purification and detection. Its hydrophilic, compact structure allows high-affinity antibody recognition without disrupting protein function. This article details molecular rationale, evidence, and best practices for workflow integration.

• Q-VD-OPh: Pan-Caspase Inhibitor Elevating Apoptosis Research

  2026-05-13

  Q-VD-OPh, a potent pan-caspase inhibitor from APExBIO, empowers researchers to precisely modulate apoptotic pathways in both in vitro and in vivo models. Its unmatched selectivity, brain permeability, and robust inhibition profile transform workflows in apoptosis research, neurodegeneration studies, and cell viability enhancement.

• Panobinostat Disrupts Epigenetic Maintenance in MLL-ALL via

  2026-05-12

  This study demonstrates that panobinostat, a histone deacetylase inhibitor, exhibits potent anti-leukaemic effects against MLL-rearranged acute lymphoblastic leukaemia (ALL) in vivo. By suppressing the RNF20/RNF40/WAC-mediated H2B ubiquitination axis, panobinostat cross-inhibits multiple epigenetic pathways, highlighting a mechanistic vulnerability and a promising therapeutic avenue for this high-risk paediatric leukaemia subtype.

15776 records 1/1052 page Next 12345 下5页 Last page